Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma.
Monoclonal antibodies labeled with radionuclides have become an important therapeutic tool in the treatment of patients with non-Hodgkin's lymphomas (NHL). At the present time, their use in the US is approved for patients with rituximab-resistant, low-grade, follicular or transformed NHL. Encouraging responses seen in the relapsed and refractory patients have prompted their evaluation in earlier disease or in other histologic sub-types either alone or in combination with conventional chemotherapy. Additionally, they have been included as preparative regimens for stem cell transplant protocols within the context of clinical trials. This review discusses the latest clinical trials and future directions of radioimmunoconjugates in the treatment of NHL, with emphasis on US Food and Drug Administration (FDA) approved radioimmunoconjugates, namely 131I-tositumomab and 90Y-ibritumomab tiuxetan.
Santos
Edgardo S
ES
Tulane Cancer Center, Tulane University Health Sciences Center, New Orleans, LA, USA. esantos1@tulane.edu
Kharfan-Dabaja
Mohamed A
MA
Ayala
Ernesto
E
Raez
Luis E
LE
D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D016499:Radioimmunotherapy / Q000379:methods*; D011874:Radiometry; D012008:Recurrence; D013997:Time Factors; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan